M&A Deal Summary |
|
|---|---|
| Date | 2023-02-02 |
| Target | Healion Bio - Preclinical Infectious Disease Portfolio |
| Sector | Life Science |
| Buyer(s) | Tonix Pharmaceuticals |
| Sellers(s) | Healion Bio |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
| Employees | 103 |
| Revenue | 8M USD (2023) |
Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing drugs and biologics to treat and prevent human disease and alleviate suffering. Tonix’s current portfolio includes biologics to prevent infectious diseases, and small molecules and biologics to treat pain, psychiatric and addiction conditions. In 2020, Tonix announced a program to develop a potential vaccine, TNX-1800* (live modified horsepox virus vaccine for percutaneous administration) to protect against the novel coronavirus disease emerging in 2019, or COVID-19. TNX-1800 is based on Tonix’s proprietary horsepox vaccine platform and is molecularly designed to express the Spike protein of the SARS-CoV-2 virus that causes COVID-19. TNX-801* (live horsepox virus vaccine for percutaneous administration) is in development to protect against smallpox and monkeypox. Tonix Pharmaceuticals was founded in 2007 and is based in Chatham, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 2 of 2 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-06-11 |
Trigemina - Non-Addictive Migraine and Pain Treatment Programs
California, United States Trigemina, Inc. - Non-Addictive Migraine and Pain Treatment Programs comprises TNX-1900 (formerly TI-001, oxytocin solution for intranasal delivery), is a proprietary, patented enhanced formulation of nasal oxytocin, with demonstrated activity in several non-clinical studies in pain including migraine prophylaxis and neuropsychiatric models and with safety data from non-U.S. studies. |
Buy | - |
Healion Bio develops cures and preventative medicines for emerging infectious diseases. Healion Bio is based in Frederick, Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
